Could a single shot be the key to preventing HIV? The answer may be closer than you think. In FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention, we reveal the groundbreaking medical advancement reshaping how we approach HIV prevention. Ready to learn how this game-changer works—and why it matters? Let’s take a closer look.
Knowledge is power—Contact us for HIV/AIDS educational resources today! 📞🌱
TL;DR:
The FDA has approved cabotegravir extended-release (Apretude) as the first long-acting injectable PrEP for HIV prevention. Administered every 2 months, it offers a highly effective alternative to daily pills like Truvada, with up to 90% risk reduction shown in clinical trials. It benefits those with adherence challenges and offers greater privacy. Eligibility requires confirmed HIV-negative status, and consistent testing is essential to avoid drug resistance.
How does the FDA-approved injectable treatment work for HIV prevention?
The FDA-approved injectable treatment for HIV pre-exposure prevention—cabotegravir extended-release—represents a significant advancement in the fight against human immunodeficiency virus. Marketed under the brand name Apretude, it is the first long-acting injectable PrEP (pre-exposure prophylaxis) authorized in the United States.
- Mechanism of Action
Cabotegravir is classified as an integrase strand transfer inhibitor. It works by blocking the action of virus integrase enzyme, a key protein the virus uses to insert its genetic material into a person’s DNA. By preventing this integration step, cabotegravir stops the virus from replicating within the body’s immune cells. The drug is administered through an intramuscular injection, designed to release the medication slowly and maintain protective levels for up to two months per dose.
- Dosing Schedule and Initiation
The treatment begins with two initial injections of 600 mg each—one at month 1 and another at month 2. After that, a maintenance injection of 600 mg is given every 8 weeks. In some cases, an oral lead-in with tablet-form cabotegravir may be recommended for about four weeks prior to starting injections. This step helps ensure the patient tolerates the medication well before transitioning to the long-acting injectable form.
What Makes This Treatment Different from Other Methods?
The FDA-approved injectable for the virus prevention treatment marks a major shift in how pre-exposure prophylaxis can be delivered. While daily oral pills have been effective for many, they’re not ideal for everyone. This long-acting injectable offers an alternative that’s not only more convenient but also more effective in clinical trials.
- Elimination of Daily Pill Burden
Unlike oral PrEP options such as Truvada or Descovy, which require daily dosing, cabotegravir injections are administered only once every two months. This long-acting schedule significantly reduces the challenge of adhering to a daily medication routine and helps ensure consistent protection without the stress of remembering pills each day. - Superior Efficacy
Clinical trials have shown the injectable treatment to be more effective than daily oral PrEP. In the HPTN 083 study, which involved men and transgender women who have sex with men, the injectable reduced risk by 69%. The HPTN 084 trial, focusing on cisgender women, reported an even greater 90% reduction in risk, highlighting the treatment’s strong protective potential across diverse populations. - Discretion and Convenience
For many, injections offer a more private and less stigmatizing option. The absence of daily pill bottles reduces the likelihood of unintended disclosure, and fewer pharmacy visits simplify the treatment process. This can make it more accessible and sustainable, especially for those concerned about confidentiality or routine management.
Who Can Use the Injectable HIV Prevention Treatment?
The FDA-approved injectable HIV prevention treatment, Apretude, is designed for individuals who are HIV-negative and at substantial risk of the virus infection. It is approved for use in both adults and adolescents who weigh at least 35 kg (approximately 77 lb).
Clinical trials supporting its approval included a diverse group of participants—such as cisgender men who have sex with men, transgender women, and cisgender women—who were identified as being at substantial risk for HIV. While the FDA label includes adolescents who meet the weight requirement, specific clinical trial data for this group remains limited.
Importantly, each injection must be preceded by a confirmed negative HIV-1 test. This precaution is essential to ensure the treatment is not initiated during an undiagnosed human immunodeficiency virus infection, which could contribute to the development of drug-resistant strains.
Benefits and Side Effects of the Injectable Treatment
The injectable prevention treatment offers several advantages, particularly for individuals who may struggle with adherence to daily oral PrEP. Its high effectiveness has been demonstrated even among populations facing challenges such as depression, substance use, or socioeconomic barriers. With only six doses required per year, the treatment provides a more convenient option and offers greater discretion—helping reduce stigma and concerns around privacy.
- Adverse Reactions and Safety Notes
Most commonly, users may experience injection-site reactions like pain, redness, or swelling, which are generally mild and temporary. Other reported side effects include headache, fatigue, fever, nausea, diarrhea, myalgia, rash, migraine, and insomnia. While these are typically manageable, some individuals did discontinue treatment due to adverse events—about 6% in one major trial and 1% in another. - Warnings and Considerations
The treatment must only begin after a confirmed negative HIV-1 test to avoid initiating therapy during undiagnosed infection. There is a concern about the potential for drug-resistant HIV if someone becomes infected during the slow drug “tail” after stopping injections or during an undetected acute infection. Careful monitoring and consistent HIV testing are essential to ensure safe and effective use.
How Has Clinical Research Proven Its Effectiveness?
The effectiveness of the FDA-approved injectable treatment has been solidly established through two pivotal clinical trials—HPTN 083 and HPTN 084. HPTN 083 included approximately 4,566 cisgender men and transgender women, and it was halted early when the injectable showed a 69% lower rate of human immunodeficiency virus acquisition compared to daily oral PrEP. Similarly, HPTN 084 enrolled around 3,224 cisgender women and was also stopped early due to a remarkable 90% risk reduction in the injectable group.
These compelling results led to swift regulatory and global health responses. In December 2021, the FDA approved the long-acting injectable for individuals who meet the eligibility criteria. Following this, the World Health Organization (WHO) issued formal guidelines in 2022 endorsing injectable cabotegravir (CAB-LA) as an additional prevention option for those at substantial risk of HIV, citing its strong clinical performance, user acceptability, and feasibility for broader implementation.
Key Takeaways
- FDA Approval: The FDA approved cabotegravir extended-release (brand name Apretude) in December 2021 as the first long-acting injectable for HIV pre-exposure prevention (PrEP) in the U.S.
- How It Works: Cabotegravir blocks HIV’s integrase enzyme, preventing the virus from integrating into the body’s DNA. Administered via intramuscular injection, it maintains protective drug levels for up to two months.
- Dosing Schedule: The regimen starts with two 600 mg injections one month apart, followed by maintenance doses every 8 weeks. A 4-week oral lead-in may be used to assess drug tolerance.
- Compared to Oral PrEP:
- Injections eliminate the need for daily pills like Truvada or Descovy.
- Clinical trials showed superior efficacy: 69% risk reduction (HPTN 083) and 90% reduction (HPTN 084).
- Offers more discretion and convenience, reducing stigma and simplifying adherence.
- Who Can Use It:
- Approved for adults and adolescents ≥35 kg who are HIV-negative.
- Includes individuals at substantial risk such as cisgender men who have sex with men, transgender women, and cisgender women.
- A negative test is required before each injection to avoid resistance risk.
- Benefits:
- High efficacy, fewer doses (every 2 months), and more privacy.
- May improve adherence in populations facing mental health or socioeconomic barriers.
- Side Effects:
- Common: injection-site reactions (pain, redness, swelling), headache, fever, fatigue, nausea, etc.
- Discontinuation rates due to side effects were ~6% (HPTN 083) and ~1% (HPTN 084).
- Warnings:
- Must not be started during undiagnosed HIV infection.
- Risk of drug-resistant HIV if infected during the drug’s long-acting “tail” phase after stopping injections.
- Clinical Trial Evidence:
- HPTN 083 and 084 showed significantly reduced human immunodeficiency virus acquisition compared to oral PrEP.
- Trials were stopped early due to strong efficacy results.
- WHO formally endorsed cabotegravir in 2022 as a PrEP option and highlighted its global potential.
Sources.
Lorenzetti, L., Dinh, N., van der Straten, A., Fonner, V., Ridgeway, K., Rodolph, M., … & Baggaley, R. (2023). Systematic review of the values and preferences regarding the use of injectable pre‐exposure prophylaxis to prevent HIV acquisition. Journal of the International AIDS Society, 26, e26107.
Bleasdale, J., McCole, M., Cole, K., Hequembourg, A., Morse, G. D., & Przybyla, S. M. (2024). Perspectives on injectable HIV pre-exposure prophylaxis: A qualitative study of health care providers in the united States. AIDS Patient Care and STDs, 38(4), 177-184.